354 related articles for article (PubMed ID: 24913502)
21. Dosage of high-dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse.
Wilson MR; Kirkwood AA; Wong Doo N; Soussain C; Choquet S; Lees C; Fox C; Preston G; Ahearne M; Strüßmann T; Clavert A; Rusconi C; Ku M; Khwaja J; Narkhede M; Lewis K; Durot E; Smith J; Renaud L; Ferreri AJM; El-Galaly T; Cwynarski K; McKay P; Eyre TA
Am J Hematol; 2024 Feb; 99(2):E46-E50. PubMed ID: 38037530
[No Abstract] [Full Text] [Related]
22. Combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma.
Dhaliwal HS; Rohatiner AZ; Gregory W; Richards MA; Johnson PW; Whelan JS; Gallagher CJ; Matthews J; Ganesan TS; Barnett MJ
Br J Cancer; 1993 Oct; 68(4):767-74. PubMed ID: 8398705
[TBL] [Abstract][Full Text] [Related]
23. Controversies in central nervous system prophylaxis of high-risk diffuse large B-cell lymphoma.
Bobillo S; Wilson MR; Cwynarski K
Curr Opin Oncol; 2023 Sep; 35(5):382-388. PubMed ID: 37551947
[TBL] [Abstract][Full Text] [Related]
24. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group.
Reiter A; Schrappe M; Ludwig WD; Lampert F; Harbott J; Henze G; Niemeyer CM; Gadner H; Müller-Weihrich S; Ritter J
Blood; 1992 Nov; 80(10):2471-8. PubMed ID: 1421370
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin's lymphoma.
Colgan JP; Andersen J; Habermann TM; Earle JD; O'Connell MJ; Neiman RS; Mann RB; Glick JH
Leuk Lymphoma; 1994 Oct; 15(3-4):291-6. PubMed ID: 7866277
[TBL] [Abstract][Full Text] [Related]
26. Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis.
Thieblemont C; Altmann B; Frontzek F; Renaud L; Chartier L; Ketterer N; Récher C; Poeschel V; Fitoussi O; Held G; Casasnovas O; Haioun C; Morschhauser F; Glass B; Mounier N; Tilly H; Rosenwald A; Ott G; Lenz G; Molina T; Ziepert M; Schmitz N
Blood Adv; 2023 Aug; 7(15):3968-3977. PubMed ID: 36716220
[TBL] [Abstract][Full Text] [Related]
27. IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma.
Conconi A; Chiappella A; Ferreri AJM; Stathis A; Botto B; Sassone M; Gaidano G; Balzarotti M; Merli F; Tucci A; Vanazzi A; Tani M; Bruna R; Orsucci L; Cabras MG; Celli M; Annibali O; Liberati AM; Zanni M; Ghiggi C; Pisani F; Pinotti G; Dore F; Esposito F; Pirosa MC; Cesaretti M; Bonomini L; Vitolo U; Zucca E
Blood Adv; 2024 Mar; 8(6):1541-1549. PubMed ID: 38181782
[TBL] [Abstract][Full Text] [Related]
28. Central Nervous System International Prognostic Index Impacts Overall Survival in Diffuse Large B-cell Lymphoma Treated with R-Chop in a third Level Cancer Center from Mexico: A Survey of 642 Patients.
Solís-Armenta R; Cacho-Díaz B; Gutiérrez-Hernández O; Candelaria-Hernández M
Rev Invest Clin; 2021 Apr; 73(4):231-237. PubMed ID: 33845484
[TBL] [Abstract][Full Text] [Related]
29. Primary breast lymphoma: a report of 20 cases.
Ribrag V; Bibeau F; El Weshi A; Frayfer J; Fadel C; Cebotaru C; Laribi K; Fenaux P
Br J Haematol; 2001 Nov; 115(2):253-6. PubMed ID: 11703318
[TBL] [Abstract][Full Text] [Related]
30. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia.
Cortes J; O'Brien SM; Pierce S; Keating MJ; Freireich EJ; Kantarjian HM
Blood; 1995 Sep; 86(6):2091-7. PubMed ID: 7662956
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent-based analysis.
Jeong H; Cho H; Kim H; Chae H; Lee JB; Lee K; Kim S; Lee SW; Ryu JS; Kim KW; Chae EJ; Huh J; Park CS; Yoon DH; Suh C
Blood Adv; 2021 Apr; 5(8):2142-2152. PubMed ID: 33881464
[TBL] [Abstract][Full Text] [Related]
32. Secondary central nervous system involvement in patients with diffuse large B-cell lymphoma treated with rituximab combined CHOP therapy - a supplementary analysis of JCOG0601.
Shimada K; Ohmachi K; Machida R; Ota S; Itamura H; Tsujimura H; Takayama N; Shimada T; Kurosawa M; Tabayashi T; Shimoyama T; Ohshima K; Miyazaki K; Maruyama D; Kinoshita T; Ando K; Hotta T; Tsukasaki K; Nagai H
Ann Hematol; 2024 Jun; 103(6):2021-2031. PubMed ID: 38280061
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic management of refractory or relapsed primary central nervous system lymphomas.
Reni M; Ferreri AJ
Ann Hematol; 2001; 80 Suppl 3():B113-7. PubMed ID: 11757691
[TBL] [Abstract][Full Text] [Related]
34. Rituximab in heavily pretreated cutaneous B-cell lymphoma.
Zinzani PL; Stefoni V; Alinari L; Vianelli N; Baccarani M
Leuk Lymphoma; 2003 Sep; 44(9):1637-8. PubMed ID: 14565673
[No Abstract] [Full Text] [Related]
35. Diffuse large B-cell lymphoma at risk of secondary CNS involvement: The inefficacy of intravenous high-dose methotrexate CNS prophylaxis and the importance of baseline cerebrospinal fluid analysis.
Bennett R; Ruskova A; Coomarasamy C; Theakston E; Berkahn L; Jackson S; Christophers M; Wong S; Issa S
Am J Hematol; 2023 Jul; 98(7):1070-1079. PubMed ID: 37161765
[TBL] [Abstract][Full Text] [Related]
36. Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma.
Puckrin R; El Darsa H; Ghosh S; Peters A; Owen C; Stewart D
Am J Hematol; 2021 Jul; 96(7):764-771. PubMed ID: 33811794
[TBL] [Abstract][Full Text] [Related]
37. Stage III abdominal non-Hodgkin's lymphoma in Costa Rican children: comparison of two consecutive trials of treatment.
Lobo-Sanahuja F; García I; Barrantes JC; Barrantes M; Jiménez R; Argüello A
Med Pediatr Oncol; 1994; 22(3):194-9. PubMed ID: 8272009
[TBL] [Abstract][Full Text] [Related]
38. Factors Influencing Physician Discretion to Administer CNS Prophylaxis in Diffuse Large B Cell Lymphoma: A Single Institution Retrospective Study.
Hino C; Lacy C; Brothers J; Cao H; Mirshahidi H; Park K; Akhtari M
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):764-771. PubMed ID: 37482525
[TBL] [Abstract][Full Text] [Related]
39. Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis.
Fang Y; Su N; Ma S; Cai J; Zhong L; Li W; Huang H; Li Z; Huang H; Xia Y; Liu P; Guo L; Li Z; Wu Y; Tian X; Wang J; Zhang Y; Cai Q
Ann Hematol; 2022 Mar; 101(3):595-605. PubMed ID: 34985557
[TBL] [Abstract][Full Text] [Related]
40. Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP).
Armitage JO; Dick FR; Corder MP; Garneau SC; Platz CE; Slymen DJ
Cancer; 1982 Nov; 50(9):1695-702. PubMed ID: 6749279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
